DYN
Dyne Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$24.28
−2.69%Jul 28, 2026, 11:30 UTC
Dyne Therapeutics received U.S. FDA clearance of its Investigational New Drug application for DYNE-302 in facioscapulohumeral muscular dystrophy.
Source:Jul 26, 2026, 23:53 UTC
Dyne Therapeutics priced an upsized underwritten public offering of 18,300,000 shares of common stock at $20.50 per share, expecting gross proceeds of $375,150,000.
Source:Jul 21, 2026, 20:46 UTC
Dyne Therapeutics announced an underwritten public offering of $300 million of its common stock, with an underwriter option for an additional $45 million.
Jul 20, 2026, 11:30 UTC
The U.S. FDA accepted for review the Biologics License Application for Dyne Therapeutics' z-rostudirsen for Duchenne muscular dystrophy amenable to exon 51 skipping, granting priority review with a PDUFA target action date of January 21, 2027.
Jun 17, 2026, 00:00 UTC
Dyne Therapeutics amended its loan and security agreement, expanding the total facility to up to $400 million, borrowing $50 million at closing, and modifying covenants.
Source: